HUTCHMED Reports 66% Response Rate in Phase III Anemia Trial
Question
HUTCHMED Reports 66% Response Rate in Phase III Anemia Trial
Direct answer
Equity value creation through successful clinical trial outcomes and regulatory progress. — bullish pressure on HCM via clinical trial success and regulatory advancement.
- Original publisher
- Market Ontology
- Evidence through
- 2026-06-12
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “HUTCHMED Reports 66% Response Rate in Phase III Anemia Trial”, revision 1, evidence through 2026-06-12. https://marketontology.com/catalysts/2026-06-12/hutchmed-reports-66-response-rate-in-phase-iii-anemia-trial-8df918
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| HCM | ▲Bull | 1–4 weeks | clinical trial success and regulatory advancement | 75 |
HUTCHMED Reports 66% Response Rate in Phase III Anemia Trial
Equity value creation through successful clinical trial outcomes and regulatory progress. — bullish pressure on HCM via clinical trial success and regulatory advancement.
HUTCHMED announced positive Phase III results for sovleplenib.
- SourceHUTCHMED announced positive Phase III results for sovleplenib.
- TransmissionEquity value creation through successful clinical trial outcomes and regulatory progress.
- SummaryHUTCHMED's anemia drug significantly outperformed placebo in a late-stage trial. The 66% response rate is a strong signal for potential market dominance in wAIHA. Regulatory approval in China appears to be the next major catalyst.
- HCMDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- HCM closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- HCM price vs. pre-event level
- HCM volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| HCM | Bullishagreed | 10.96 2026-06-12 | -1.19% | -8.85% | +2.65% |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed a KRAS-EGFR license with GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR conjugate license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.